HUE045270T2 - FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére - Google Patents
FLT3 receptor anatgonisták fájdalom rendellenességek kezeléséreInfo
- Publication number
- HUE045270T2 HUE045270T2 HUE11700121A HUE11700121A HUE045270T2 HU E045270 T2 HUE045270 T2 HU E045270T2 HU E11700121 A HUE11700121 A HU E11700121A HU E11700121 A HUE11700121 A HU E11700121A HU E045270 T2 HUE045270 T2 HU E045270T2
- Authority
- HU
- Hungary
- Prior art keywords
- prevention
- treatment
- receptor antagonists
- pain disorders
- flt3 receptor
- Prior art date
Links
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 title 1
- 208000027520 Somatoform disease Diseases 0.000 title 1
- 208000027753 pain disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5032—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on intercellular interactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10305013 | 2010-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE045270T2 true HUE045270T2 (hu) | 2019-12-30 |
Family
ID=42173594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE11700121A HUE045270T2 (hu) | 2010-01-05 | 2011-01-05 | FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére |
Country Status (4)
Country | Link |
---|---|
US (2) | US9109227B2 (hu) |
EP (1) | EP2521782B1 (hu) |
HU (1) | HUE045270T2 (hu) |
WO (1) | WO2011083124A1 (hu) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10106798B2 (en) * | 2010-01-05 | 2018-10-23 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | FLT3 receptor antagonists for the treatment or the prevention of pain disorders |
EP3174859B1 (en) * | 2014-07-31 | 2020-04-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Flt3 receptor antagonists |
EP3254698A1 (en) | 2016-06-08 | 2017-12-13 | Universite De Montpellier | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
BR112018076306A2 (pt) | 2016-06-17 | 2019-03-26 | Magenta Therapeutics, Inc. | composições e métodos para a supressão de células cd117+ |
KR102725761B1 (ko) | 2017-01-20 | 2024-11-04 | 하이델베르크 파마 리서치 게엠베하 | Cd137+ 세포의 고갈을 위한 조성물 및 방법 |
CA3062981A1 (en) * | 2017-05-17 | 2018-11-22 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Flt3 inhibitors for improving pain treatments by opioids |
EP3630841A1 (en) | 2017-06-02 | 2020-04-08 | Pfizer Inc. | Antibodies specific for flt3 and their uses |
EP4353712A1 (en) | 2022-10-11 | 2024-04-17 | Biodol Therapeutics | New n-heteroarylbenzamides derivatives as flt3 inhibitors |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
US6740756B1 (en) | 1998-07-07 | 2004-05-25 | Smithkline Beecham Corporation | Fluorescent lanthanide chelates |
EP1095011A4 (en) | 1998-07-07 | 2003-01-08 | Smithkline Beecham Corp | NEW FLUORESCENT LANTHANIDE CHELATES |
US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
EP1328519B1 (en) | 2000-10-17 | 2005-09-07 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
WO2003024969A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
IL161156A0 (en) | 2001-10-30 | 2004-08-31 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
PL208283B1 (pl) | 2001-12-27 | 2011-04-29 | Theravance | Pochodna indolinonu, sposób jej wytwarzania, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca i zastosowanie tej kompozycji |
AR037647A1 (es) | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
EP1546117A2 (en) | 2002-08-14 | 2005-06-29 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
KR20050037585A (ko) | 2002-08-23 | 2005-04-22 | 카이론 코포레이션 | 벤지미다졸 퀴놀리논 및 그들의 사용 |
WO2004039782A1 (ja) | 2002-10-29 | 2004-05-13 | Kirin Beer Kabushiki Kaisha | Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
WO2004043389A2 (en) | 2002-11-13 | 2004-05-27 | Chiron Corporation | Methods of treating cancer and related methods |
CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
ATE425160T1 (de) | 2002-12-18 | 2009-03-15 | Vertex Pharma | Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen |
US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
US7795279B2 (en) | 2005-10-18 | 2010-09-14 | Janssen Pharmaceutica Nv | Method of inhibiting FLT3 kinase |
CA2646437C (en) | 2006-03-17 | 2016-05-17 | Ambit Biosciences Corporation | Imidazolothiazole compounds for the treatment of disease |
CA2649924C (en) | 2006-04-20 | 2014-08-19 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
EP2222298A1 (en) | 2007-11-02 | 2010-09-01 | Janssen Pharmaceutica N.V. | Use of cfms inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer |
AR069244A1 (es) | 2007-11-08 | 2010-01-06 | Ambit Biosciences Corp | Metodos para administrar n-( 5- ter- butil- isoxixasol-3-il) -n'- (4(7-(2- morfolin-4-il- etoxi) imidazo (2,1-b) (1,3) benzotiazol -2-il) fenil) urea para tratar una enfermedad proliferante y composicion farmaceutica |
EP2068152A1 (en) | 2007-12-06 | 2009-06-10 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | c-Kit as a novel target for the treatment of pain |
EP2252597B1 (en) | 2008-02-01 | 2014-03-19 | Akinion Pharmaceuticals AB | Pyrazine derivatives and their use as protein kinase inhibitors |
JP2011515337A (ja) | 2008-02-29 | 2011-05-19 | サイレーン ファーマシューティカルズ, インコーポレイテッド | プロテインキナーゼモジュレーター |
AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
-
2011
- 2011-01-05 US US13/520,598 patent/US9109227B2/en active Active
- 2011-01-05 EP EP11700121.4A patent/EP2521782B1/en active Active
- 2011-01-05 HU HUE11700121A patent/HUE045270T2/hu unknown
- 2011-01-05 WO PCT/EP2011/050103 patent/WO2011083124A1/en active Application Filing
-
2015
- 2015-07-08 US US14/793,823 patent/US9765339B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2521782B1 (en) | 2019-04-10 |
US9109227B2 (en) | 2015-08-18 |
US20150307887A1 (en) | 2015-10-29 |
WO2011083124A1 (en) | 2011-07-14 |
US9765339B2 (en) | 2017-09-19 |
EP2521782A1 (en) | 2012-11-14 |
US20130052205A1 (en) | 2013-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2467372T (pt) | Tratamento de distúrbios relacionados com bdnf usando laquinimod | |
HRP20181608T1 (hr) | Korištenje inhibitora pde7 u liječenju bolesti kretanja | |
IL217768A (en) | Coinimod for the treatment of Crohn's disease | |
HUE036040T2 (hu) | Adaptor-asszociált kináz 1 gátlása fájdalom kezelésére | |
HK1215787A1 (zh) | 用於治療疼痛的藥物組合 | |
EP2166837A4 (en) | DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS | |
EP2827856A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCLE DISEASES | |
HUE045270T2 (hu) | FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére | |
IL232334A0 (en) | Modulators of the G protein-coupled mas receptor and the treatment of related disorders | |
HK1186671A1 (en) | Formulations for the treatment of disorders of the upper respiratory tract | |
HK1182015A1 (zh) | 活性藥物化合物用於治療中樞神經系統病症的用途 | |
IL222890A0 (en) | Medicaments for the treatment of il-1beta related conditions | |
IL225896A0 (en) | Treatment of mecp-2 related disorders | |
EP2681209A4 (en) | COMPOUNDS AND METHODS FOR TREATING PAIN AND OTHER DISEASES | |
IL225755B (en) | amido derivatives - 6 of epoxymorphinans - a5, 4 for the treatment of pain | |
IL215990A0 (en) | Phosphotetrahydfropyran compounds for the treatment of wounds and fibrotic disorders | |
EP2578206A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISORDERS OF THE LOWER PART OF THE UROGENITAL SYSTEM | |
WO2011091401A9 (en) | Treatment of immune disorders using kainate receptor antagonists | |
EP2459507A4 (en) | USE OF ERYTHRITOL FOR THE PREVENTION OR TREATMENT OF HYPERTONIA | |
ZA201304121B (en) | Arlysulfonamide derivatives for the prevention or treatment of specific ophthalmologic disorders | |
GB201007205D0 (en) | Treatment of joint disorders | |
IL223055A0 (en) | Compositions for the treatment of gynaecological disorders |